|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KCNQ1OT1 |
Gene summary for KCNQ1OT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KCNQ1OT1 | Gene ID | 10984 |
| Gene name | KCNQ1 opposite strand/antisense transcript 1 | |
| Gene Alias | KCNQ1-AS2 | |
| Cytomap | 11p15.5 | |
| Gene Type | ncRNA | GO ID | GO:0006139 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10984 | KCNQ1OT1 | GSM4909285 | Human | Breast | IDC | 4.77e-24 | 5.63e-01 | 0.21 |
| 10984 | KCNQ1OT1 | GSM4909286 | Human | Breast | IDC | 3.52e-11 | -3.27e-01 | 0.1081 |
| 10984 | KCNQ1OT1 | GSM4909293 | Human | Breast | IDC | 6.97e-17 | 4.00e-01 | 0.1581 |
| 10984 | KCNQ1OT1 | GSM4909295 | Human | Breast | IDC | 2.28e-04 | 4.62e-01 | 0.0898 |
| 10984 | KCNQ1OT1 | GSM4909298 | Human | Breast | IDC | 1.55e-31 | 7.12e-01 | 0.1551 |
| 10984 | KCNQ1OT1 | GSM4909311 | Human | Breast | IDC | 7.71e-11 | -3.29e-01 | 0.1534 |
| 10984 | KCNQ1OT1 | GSM4909312 | Human | Breast | IDC | 2.23e-08 | -3.25e-01 | 0.1552 |
| 10984 | KCNQ1OT1 | GSM4909315 | Human | Breast | IDC | 1.03e-07 | -3.14e-01 | 0.21 |
| 10984 | KCNQ1OT1 | GSM4909317 | Human | Breast | IDC | 6.46e-15 | 5.37e-01 | 0.1355 |
| 10984 | KCNQ1OT1 | GSM4909319 | Human | Breast | IDC | 7.71e-11 | -2.98e-01 | 0.1563 |
| 10984 | KCNQ1OT1 | brca10 | Human | Breast | Precancer | 5.71e-03 | -2.77e-01 | -0.0029 |
| 10984 | KCNQ1OT1 | NCCBC14 | Human | Breast | DCIS | 1.73e-08 | -1.28e-01 | 0.2021 |
| 10984 | KCNQ1OT1 | NCCBC5 | Human | Breast | DCIS | 1.30e-07 | -3.08e-01 | 0.2046 |
| 10984 | KCNQ1OT1 | DCIS2 | Human | Breast | DCIS | 3.27e-38 | 6.14e-01 | 0.0085 |
| 10984 | KCNQ1OT1 | CCI_1 | Human | Cervix | CC | 3.77e-04 | 2.97e-01 | 0.528 |
| 10984 | KCNQ1OT1 | CCI_2 | Human | Cervix | CC | 2.86e-05 | 4.37e-01 | 0.5249 |
| 10984 | KCNQ1OT1 | CCI_3 | Human | Cervix | CC | 1.65e-18 | 6.72e-01 | 0.516 |
| 10984 | KCNQ1OT1 | Tumor | Human | Cervix | CC | 8.77e-10 | 1.96e-01 | 0.1241 |
| 10984 | KCNQ1OT1 | sample1 | Human | Cervix | CC | 2.17e-17 | 6.08e-01 | 0.0959 |
| 10984 | KCNQ1OT1 | sample3 | Human | Cervix | CC | 5.84e-20 | 3.89e-01 | 0.1387 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00467009 | Endometrium | AEH | heterocycle catabolic process | 79/2100 | 445/18723 | 2.27e-05 | 4.35e-04 | 79 |
| GO:00194399 | Endometrium | AEH | aromatic compound catabolic process | 80/2100 | 467/18723 | 7.21e-05 | 1.10e-03 | 80 |
| GO:19013619 | Endometrium | AEH | organic cyclic compound catabolic process | 83/2100 | 495/18723 | 1.13e-04 | 1.60e-03 | 83 |
| GO:00105865 | Endometrium | AEH | miRNA metabolic process | 10/2100 | 27/18723 | 4.29e-04 | 4.55e-03 | 10 |
| GO:00105873 | Endometrium | AEH | miRNA catabolic process | 5/2100 | 12/18723 | 7.10e-03 | 4.09e-02 | 5 |
| GO:000989617 | Endometrium | EEC | positive regulation of catabolic process | 108/2168 | 492/18723 | 2.55e-11 | 3.64e-09 | 108 |
| GO:003133117 | Endometrium | EEC | positive regulation of cellular catabolic process | 94/2168 | 427/18723 | 4.30e-10 | 4.45e-08 | 94 |
| GO:000640115 | Endometrium | EEC | RNA catabolic process | 65/2168 | 278/18723 | 1.90e-08 | 1.16e-06 | 65 |
| GO:004427013 | Endometrium | EEC | cellular nitrogen compound catabolic process | 83/2168 | 451/18723 | 1.17e-05 | 2.43e-04 | 83 |
| GO:004670013 | Endometrium | EEC | heterocycle catabolic process | 82/2168 | 445/18723 | 1.26e-05 | 2.55e-04 | 82 |
| GO:003465514 | Endometrium | EEC | nucleobase-containing compound catabolic process | 76/2168 | 407/18723 | 1.61e-05 | 3.12e-04 | 76 |
| GO:001943913 | Endometrium | EEC | aromatic compound catabolic process | 83/2168 | 467/18723 | 4.32e-05 | 7.10e-04 | 83 |
| GO:190136113 | Endometrium | EEC | organic cyclic compound catabolic process | 86/2168 | 495/18723 | 7.31e-05 | 1.07e-03 | 86 |
| GO:001058613 | Endometrium | EEC | miRNA metabolic process | 11/2168 | 27/18723 | 1.08e-04 | 1.49e-03 | 11 |
| GO:001058712 | Endometrium | EEC | miRNA catabolic process | 5/2168 | 12/18723 | 8.14e-03 | 4.49e-02 | 5 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
| GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
| GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
| GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |